NCT02128022

Cardioprotective Effects of GLP-1 and Their Mechanisms

Investigation Into Cardioprotective Effect of Glucagon-like Peptide-1 and it's Mechanism of Action During Myocardial Ischaemia

• Status: Completed
• Phase: Phase 1
• Study type: Interventional
• Enrollment: 32 (actual)
• Sponsor: Papworth Hospital NHS Foundation Trust · Other Government
• Sex: All
• Age: 18 Years
• Healthy volunteers: Not accepted

Summary

Ischaemic heart disease is the most common cause of death in the UK. Glucagon-like peptide-1 (GLP-1) has been demonstrated to protect the heart when it is deprived of blood supply (ischaemia). The mechanism for this protection is not clear. Similar protection occurs with ischaemic conditioning of the heart, which is dependent on potassium channel opening. The investigators intend to establish whether GLP-1 mediated protection shares a similar mechanistic pathway. In order to do this the investigators will measures pressure--volume loops generated in the main pumping chamber of the heart at the time of a percutaneous coronary intervention (stenting). Patients will be allocated to GLP-1 alone, GLP-1 with glibenclamide (a potassium channel blocking medication approved for human use), saline control or glibenclamide alone. The investigators hypothesis is that the effect of GLP-1 will be abrogated by use of glibenclamide.

Conditions

• Angina Pectoris

Interventions

Type	Name	Description
DRUG	GLP-1 (7-36) amide	Infusion of GLP-1 (7-36) amide 1.2 pmol/Kg/min
DRUG	Glibenclamide	Oral Glibenclamide 5mg

Timeline

• Start date: 2014-07-01
• Primary completion: 2016-03-01
• Completion: 2016-03-01
• First posted: 2014-05-01
• Last updated: 2016-04-11

Locations

1 site across 1 country: United Kingdom